Republican lawmakers are sharply criticizing the Food and Drug Administration’s relationship with a nonprofit group seeking to create a network of laboratories to test artificial intelligence products used in health care.
In a letter sent Tuesday, the lawmakers asserted that the agency’s budding partnership with the nonprofit Coalition for Health AI (CHAI) will embed a “clear conflict of interest” into the process of scrutinizing AI tools. The letter points out that the organization is composed of technology companies such as Microsoft and Google, as well as large health care systems that incubate AI businesses.
Troy Tazbaz, director of the FDA’s Digital Health Center of Excellence, serves on CHAI’s board as a federal liaison.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect